Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus ELOCON.
ACLOVATE vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid